Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Transfer factor in Hodgkin's disease.

R P Ng, C J Moran, C G Alexopoulos

    Lancet (London, England)
    |November 8, 1975
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Anaesthesia for the maternal-assisted caesarean section.

    International journal of obstetric anesthesia·2024
    Same author

    Wide Variability in Prethrombectomy Workflow Practices in the United States: A Multicenter Survey.

    AJNR. American journal of neuroradiology·2017
    Same author

    Can members of the south-western Gila robusta species complex be distinguished by morphological features?

    Journal of fish biology·2017
    Same author

    Flow Diversion in Ruptured Intracranial Aneurysms: A Meta-Analysis.

    AJNR. American journal of neuroradiology·2016
    Same author

    A history of meniscal surgery: from ancient times to the twenty-first century.

    Knee surgery, sports traumatology, arthroscopy : official journal of the ESSKA·2015
    Same author

    Retrospective review of cerebral mycotic aneurysms in 26 patients: focus on treatment in strongly immunocompromised patients with a brief literature review.

    AJNR. American journal of neuroradiology·2012
    Same journal

    Assisted dying and the silencing of medicine's next generation.

    Lancet (London, England)·2026
    Same journal

    Linguistic pragmatism: a woman with progressive abdominal pain in Thailand.

    Lancet (London, England)·2026
    Same journal

    Medical compartmentalisation: a patient with chromosome 22q11.2 deletion syndrome in Japan.

    Lancet (London, England)·2026
    Same journal

    [<sup>177</sup>Lu]Lu-edotreotide versus everolimus for gastroenteropancreatic neuroendocrine tumours (COMPETE): a phase 3, multicentre, randomised, open-label, superiority trial.

    Lancet (London, England)·2026
    Same journal

    Research priorities for characterising Bundibugyo virus.

    Lancet (London, England)·2026
    Same journal

    Rethinking treatment sequence in advanced gastroenteropancreatic neuroendocrine tumours.

    Lancet (London, England)·2026
    See all related articles

    Transfer factor (TF) therapy showed promise for advanced Hodgkin's disease by boosting immune responses. Three patients experienced improved cell-mediated immunity, suggesting TF as a potential treatment for this cancer.

    Area of Science:

    • Immunology
    • Oncology
    • Cellular Biology

    Background:

    • Hodgkin's disease is a cancer of the lymphatic system.
    • Advanced stages (stage IV) present significant treatment challenges.
    • Cell-mediated immunity plays a crucial role in cancer surveillance and response.

    Purpose of the Study:

    • To evaluate the safety and efficacy of transfer factor (TF) in patients with stage IV Hodgkin's disease.
    • To assess the impact of TF on cell-mediated immune responses in these patients.
    • To explore TF as a potential immunotherapeutic agent for Hodgkin's disease.

    Main Methods:

    • A controlled study involving six patients with stage IV Hodgkin's disease.
    • Administration of transfer factor (TF) derived from donors in long-term remission from Hodgkin's disease.

    Related Experiment Videos

  • Assessment of cell-mediated immunity through lymphocyte proliferation assays (phytohaemagglutinin stimulation) and delayed-hypersensitivity skin tests.

    • Main Results:

    • An observable increase in cell-mediated immune responses in recipients.
    • Significant enhancement of lymphocyte responses to phytohaemagglutinin stimulation.
    • Three out of six patients demonstrated conversion to positive delayed-hypersensitivity tests, particularly those with nodular sclerosing Hodgkin's disease.

    Conclusions:

    • Transfer factor (TF) therapy may enhance immune responses in patients with advanced Hodgkin's disease.
    • The observed immune modulation suggests TF's potential as an adjunctive therapy.
    • Further investigation into Hodgkin's disease-specific TF is warranted for its therapeutic application.